Cargando…
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET). A post hoc analysis of the placebo arm of the RAD001 In Advanced Neuroendocrine Tumors-2 (RADIANT-2) study was conducted to asses...
Autores principales: | Strosberg, Jonathan R, Yao, James C, Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D, Ruszniewski, Philippe B, Van Cutsem, Eric, Öberg, Kjell, Pavel, Marianne E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609826/ https://www.ncbi.nlm.nih.gov/pubmed/26373569 http://dx.doi.org/10.1530/ERC-15-0314 |
Ejemplares similares
-
Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
por: Fazio, Nicola, et al.
Publicado: (2017) -
The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012) -
Pitfalls in neuroendocrine tumor diagnosis
por: Bajetta, Emilio, et al.
Publicado: (2009) -
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
por: Buzzoni, Roberto, et al.
Publicado: (2017) -
Radiant Motherhood
por: Stopes, Marie Carmichael
Publicado: (1920)